Challenges in pharmacovigilance.
作者信息
Dikshit R K
机构信息
Chief Editor, Indian Journal of Pharmacology, Department of Pharmacology, B.J. Medical College, Ahmedabad - 380 016, India. E-mail:
出版信息
Indian J Pharmacol. 2010 Dec;42(6):333. doi: 10.4103/0253-7613.71882.
Abstract
摘要
相似文献
1
Challenges in pharmacovigilance.药物警戒中的挑战。
Indian J Pharmacol. 2010 Dec;42(6):333. doi: 10.4103/0253-7613.71882.
2
A qualitative exploration of the major challenges facing pharmacovigilance in Saudi Arabia.沙特阿拉伯药物警戒面临的主要挑战的定性探索。
Saudi Med J. 2015 Sep;36(9):1097-102. doi: 10.15537/smj.2015.9.12125.
3
Pharmacovigilance in India: Present Scenario and Future Challenges.印度的药物警戒：现状与未来挑战。
Drug Saf. 2019 Mar;42(3):339-346. doi: 10.1007/s40264-018-0730-7.
4
Pharmacovigilance in India in Comparison With the USA and European Union: Challenges and Perspectives.印度与美国和欧盟的药物警戒：挑战与展望
Ther Innov Regul Sci. 2019 Nov;53(6):781-786. doi: 10.1177/2168479018812775. Epub 2018 Dec 17.
5
The Adverse Drug Reactions from Patient Reports in Social Media Project: Five Major Challenges to Overcome to Operationalize Analysis and Efficiently Support Pharmacovigilance Process.社交媒体项目中患者报告的药物不良反应：实施分析并有效支持药物警戒过程需克服的五大挑战。
JMIR Res Protoc. 2017 Sep 21;6(9):e179. doi: 10.2196/resprot.6463.
6
French pharmacovigilance: Missions, organization and perspectives.法国药物警戒：任务、组织与展望。
Therapie. 2016 Apr;71(2):143-50. doi: 10.1016/j.therap.2016.02.029. Epub 2016 Feb 20.
7
Postmarketing Safety of Biosimilars: Current Status, Challenges, and Opportunities in the Spontaneous Reporting System.生物类似药的上市后安全性：自发报告系统的现状、挑战和机遇。
Ther Innov Regul Sci. 2020 May;54(3):667-680. doi: 10.1007/s43441-019-00101-6. Epub 2020 Jan 6.
8
Pharmacovigilance in developing countries (part I): importance and challenges.发展中国家的药物警戒（第一部分）：重要性与挑战
Int J Clin Pharm. 2018 Aug;40(4):758-763. doi: 10.1007/s11096-017-0570-z.
9
Traceability of biologicals: present challenges in pharmacovigilance.生物制品的可追溯性：药物警戒中的当前挑战。
Expert Opin Drug Saf. 2015 Jan;14(1):63-72. doi: 10.1517/14740338.2015.972362. Epub 2014 Nov 5.
10
Pharmacovigilance as Scientific Discovery: An Argument for Trans-Disciplinarity.药物警戒学作为科学发现：跨学科的论据。
Drug Saf. 2019 Oct;42(10):1115-1124. doi: 10.1007/s40264-019-00826-1.
引用本文的文献
1
Adverse drug reaction profile of microtubule-damaging antineoplastic drugs: A focused pharmacovigilance study in India.微管破坏类抗肿瘤药物的药物不良反应概况：印度一项重点药物警戒研究
Indian J Pharmacol. 2016 Sep-Oct;48(5):509-514. doi: 10.4103/0253-7613.190725.
2
Clinical pharmacists: The major support to Indian healthcare system in near future.临床药剂师：近期印度医疗保健系统的主要支撑力量。
J Pharm Bioallied Sci. 2015 Jul-Sep;7(3):161-74. doi: 10.4103/0975-7406.160005.
3
Safety reporting - Making it safely effective or effectively safe?
Perspect Clin Res. 2012 Jul;3(3):85-6. doi: 10.4103/2229-3485.100640.
4
An adverse drug reaction clinic: Breathing fresh life into the pharmacovigilance programme.一个药品不良反应诊所：为药物警戒计划注入新活力。
J Pharmacol Pharmacother. 2012 Jan;3(1):74-5. doi: 10.4103/0976-500X.92501.
5
Starting a pharmacovigilance center: Actions for implementation.建立药物警戒中心：实施行动
J Pharmacol Pharmacother. 2011 Oct;2(4):295-9. doi: 10.4103/0976-500X.85945.
6
Biogenerics: Are we ready to take safety challenges in India?生物仿制药：我们准备好应对印度的安全挑战了吗？
Indian J Pharmacol. 2011 May;43(3):362-3. doi: 10.4103/0253-7613.81493.
本文引用的文献
1
Pharmacovigilance: Safety matters….药物警戒：安全至关重要……
Indian J Pharmacol. 2008 Feb;40(Suppl 1):S1-2.
Zotero 插件